Name: Four year updated relapse-free survival results support the role of adjuvant dabrafenib plus trametinib in patients with stage III BRAF V600E/Kmutant melanoma
Brand: Key Opinions in Medicine
SKU: 131325
Availability: InStock

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

Four year updated relapse-free survival results support the role of adjuvant dabrafenib plus trametinib in patients with stage III BRAF V600E/Kmutant melanomaBack

Most Read Issues